Results of LIBRETTO-531 support selpercatinib as first-line treatment in patients with RET-mutant metastatic medullary thyroid cancer

by VHIO

Findings highlight the importance of precision therapy for advanced medullary thyroid cancer as well as the molecular characterization of disease prior to treatment. Results also support selpercatinib...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Ona Therapeutics Raises $86.6 Million Se...

by Ysios Capital

Proceeds to support clinical development of lead first-in-class progra...

Photos Stream